Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes
WebcastFaculty
OVERVIEW
Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes is organized by Physicians Education Resource, LLC (PER) and will be held during Aug 31, 2017 - Aug 31, 2018.
The target audience for this medical event is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer may also participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Overview :
The management of advanced forms of lung cancer has been transformed in recent years because of remarkable developments in molecular diagnostics and new therapies. The targeting of known oncogenic drivers has allowed for the development of strategies that aim to improve efficacy and minimize toxicity compared with previous standards of care. Indeed, personalized care is now the standard of care in non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have brought hope to patients with several types of cancer in multiple lines of therapy, including epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-translocated NSCLC. Inpatient populations that have received targeted treatments, an impressive clinical benefit has been achieved with TKIs that target mutated EGFR or ALK. These changes are welcome, and the field continues to move forward, with new diagnostic techniques and an ever-expanding array of therapeutic options in the different lines of therapy. The continual advances in the treatment of patients with oncogenic driver–mutated NSCLC create practice and educational gaps for clinical oncologists who strive to maintain state-of-the-art care for their patients. To meet this educational need, this interactive live symposium has assembled internationally recognized experts in lung cancer research and care to provide cutting-edge approaches that can be applied immediately to clinical practice.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Apply clinical trial evidence for decision making to personalize care in the frontline setting of NSCLC with actionable mutations
• Outline multidisciplinary methods to facilitate tumor tissue characterization, rebiopsy, or liquid biopsies to identify actionable mutations in multiple lines of care for patients with lung cancer
• Assess current and emerging strategies to address the problem of acquired resistance and relapse in patients with NSCLC
• Personalize care via the use of tumor- and patient-specific characteristics for patients with advanced forms of NSCLC beyond disease progression
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer may also participate. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Conference Overview :
The management of advanced forms of lung cancer has been transformed in recent years because of remarkable developments in molecular diagnostics and new therapies. The targeting of known oncogenic drivers has allowed for the development of strategies that aim to improve efficacy and minimize toxicity compared with previous standards of care. Indeed, personalized care is now the standard of care in non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have brought hope to patients with several types of cancer in multiple lines of therapy, including epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-translocated NSCLC. Inpatient populations that have received targeted treatments, an impressive clinical benefit has been achieved with TKIs that target mutated EGFR or ALK. These changes are welcome, and the field continues to move forward, with new diagnostic techniques and an ever-expanding array of therapeutic options in the different lines of therapy. The continual advances in the treatment of patients with oncogenic driver–mutated NSCLC create practice and educational gaps for clinical oncologists who strive to maintain state-of-the-art care for their patients. To meet this educational need, this interactive live symposium has assembled internationally recognized experts in lung cancer research and care to provide cutting-edge approaches that can be applied immediately to clinical practice.
Conference Objectives :
At the conclusion of this activity, you should be better prepared to:
• Apply clinical trial evidence for decision making to personalize care in the frontline setting of NSCLC with actionable mutations
• Outline multidisciplinary methods to facilitate tumor tissue characterization, rebiopsy, or liquid biopsies to identify actionable mutations in multiple lines of care for patients with lung cancer
• Assess current and emerging strategies to address the problem of acquired resistance and relapse in patients with NSCLC
• Personalize care via the use of tumor- and patient-specific characteristics for patients with advanced forms of NSCLC beyond disease progression
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links